SCHEMBL23501649

SCHEMBL23501649

COC(=O)c1ccc(C)c(C(C)N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
MAPT P10636 5/20 0.47
KDM4E B2RXH2 4/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
ATM Q13315 1/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA12 O43570 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
XDH P47989 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NOTUM Q6P988 1/20 0.46
CYP2C9 P11712 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29934095 1.00 ALDH1A1 (0.47) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL6919124 0.87 GRM1 (0.49) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL16159970 0.86 CA1 (0.50) ALDH1A1MAPTKDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL2409392 0.85 GRM1 (0.47) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL19559120 0.83 MAPT (0.44) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL31691457 0.81 NOTUM (0.50) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL6919526 0.79 MAPT (0.55) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL3645994 0.79 DPP4 (0.48) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL12584012 0.79 DPP4 (0.48) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL17524486 0.79 LMNA (0.51) ALDH1A1MAPTKDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor NIPPON SHINYAKU CO., LTD. (JP) 2025-12-30 US disclosed
EP-4516777-A2 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR Nippon Shinyaku Co., Ltd. (JP) 2025-03-05 EP disclosed
US-20230101484-A1 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR NIPPON SHINYAKU CO., LTD. (JP) 2023-03-30 US disclosed
CN-115315421-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2022-11-08 CN disclosed
EP-4074376-A1 COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION Nippon Shinyaku Co., Ltd. (JP) 2022-10-19 EP disclosed
WO-2021117846-A1 COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION 日本新薬株式会社 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor PDGFRA, PDGFRB, PDGFA ALDH1A1 1938/4885MAPT 4515/4885KDM4E 713/4885
US-20230101484-A1 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR PDGFRB, PDGFRA, PDGFA ALDH1A1 2989/4885MAPT 3911/4885KDM4E 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.